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Is there a role of synovial biopsy in drug
development?
Maria Filkova1, Andrew Cope1, Tim Mant2 and James Galloway1*
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease which causes significant pain, joint deformity, functional disability.
The pathological hallmark of RA is inflammation of the synovium characterized by involvement of inflammatory and
resident stromal cells, soluble mediators and signalling pathways leading to irreversible joint destruction. The treatment
goal in RA has evolved over the last decade towards a target of disease remission that is achieved in less than a third
of patients in clinical trials. The lack of therapeutic response to current treatments is suggestive of alternative drivers of
RA pathogenesis that might serve as promising therapeutic targets. There are data to justify the use of synovial tissue
in early drug development. Synovial tissue represents an appropriate compartment to be studied in patients with
inflammatory arthritis and provides information that is distinct from peripheral blood. Modern techniques have
made the procedure much more accessible and ultrasound guided biopsies represent a safe and acceptable option.
Advances in analytic technologies allowing transcriptomic level of analysis can provide unique inside to target
organ/tissue following the exposure to investigational medicinal product. However, there are still caveats with
regard to both the choice of technique and analytical methods. Therefore the significance of synovial biopsy
remains to be determined in future clinical trials. The aim of the current debate is to explore the potential
for accessing and evaluating synovial tissue in early drug development, to summarize lessons we have learned from
clinical trials and to discuss the challenges that have arisen so far.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease,
which causes significant pain, joint deformity, functional
disability and a significant overall healthcare burden [1].
The treatment goal in RA has evolved over the last
decade towards a target of disease remission. Besides
conventional synthetic disease modifying anti-rheumatic
drugs (DMARDs), biological agents targeting cytokines
(TNF-α, IL-1, IL-6) and immune cells (B- and T-
lymphocytes) have led to remarkable patient benefits [2].
However, fewer than 30 % of patients in clinical trials
achieve disease remission [3].
Although many new agents for treating RA have been
evaluated in phase II/III clinical trials in recent years,
progression to later phase clinical research or licencing
has been limited by concerns about adverse events or
lack of therapeutic effect [4]. For example, fostamatinib,
a selective inhibitor of spleen tyrosine kinase (SYK), sup-
pressed clinical arthritis and bone erosions in a mouse
model of arthritis [5]. However, following four phase II
and three phase III clinical trials involving 3200 patients
with active RA it was felt that the agent was not worth
taking forward to market due to lack of efficacy [4]. The
reasons for drugs failing are invariably complex. How-
ever, a lack of adequate information about human
pharmacodynamics during the early stages of drug de-
velopment represents a key factor. We hypothesize that
early mechanism of action studies with a detailed under-
standing of the pharmacology of the drug within the tar-
get tissue may greatly facilitate progress through clinical
development [6, 7].
The pathological hallmark of RA is inflammation of
the synovium. This involves a crosstalk between hetero-
geneous inflammatory and resident stromal cells as well
as presence of many soluble mediators and signalling
pathways leading to irreversible joint destruction [8].
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Given this complexity, the lack of therapeutic response
to current treatments is suggestive of alternative drivers
of RA pathogenesis that might serve as promising thera-
peutic targets [9, 10].
In this debate we aimed to explore the potential for
accessing and evaluating synovial tissue in early drug
development (Fig. 1), to summarize lessons we have
learned from clinical trials and to discuss the challenges
that have arisen so far.
Discussion
The case for using synovial biopsy in drug development
In phase I clinical trials, safety and tolerability of a new
drug is assessed in healthy volunteers adopting a ‘maximum
tolerated dose’ approach that seeks to establish drug safety,
tolerability, pharmacokinetics and pharmacodynamics of a
drug and identify a suitable dose for phase II studies. Phase
II looks for signals to support the idea that the drug is effi-
cacious. Early signal of pharmacodynamic effect in target or
surrogate tissue may support the idea that the drug has effi-
cacy in patients and may help to establish dosing regimen
as shown in oncology trials [7, 11]. Based on phase II out-
comes, one or two doses are then tested in phase III trials
that will ultimately confirm efficacy in a larger target popu-
lation and provide the information required for licensure.
In addition to time needed for the drug development, it is
important to acknowledge that the journey of a drug
through these phases costs upwards of £40 million in the
current era, with an average drug taking over 7 years to
make the transition from phase 1 through to market [12].
Many of the newer agents used for treating rheumatic
diseases are monoclonal antibodies (mAb) that have no
‘maximum tolerated dose’. The general approach to select-
ing a safe human starting dose for mAbs has significantly
changed following a series of severe, life threatening adverse
events observed during a first-in-human (FIH) clinical trial
[13]. The concept of a minimal anticipated biological effect
level was coined to provide an understanding of the mini-
mum dose at which pharmacodynamic activity might be
anticipated in humans, using data derived from pre-clinical
studies in animals or in vitro studies [14].
To complicate matters, the pharmacokinetic properties
of a mAb may differ greatly between healthy volunteers
and patients with the target disease because the pharma-
cokinetics may depend upon the levels of target ligand
present and the role of the target molecule in normal
and pathophysiological condition [15, 16]. Healthy vol-
unteers may express the therapeutic target to much
lesser extent than the patients or may not express it at
all. Therefore choosing doses for subsequent study is
more challenging as too high a dose may lead not only
to early toxicity, but also the delayed effects of immune
suppression (e.g. infection or cancer). Conversely, select-
ing too low a dose may lead to a failure to demonstrate
efficacy and result in inappropriately stopping further
study of a potentially useful agent. For example, levels of
IL-17, which contributes to the pathogenesis of RA, are
extremely low or undetectable in healthy humans while
IL-17 is elevated in sera and synovial fluid of patients
with RA and IL-17 is present at site of inflammation in
Fig. 1 Validated and potential use of synovial tissue biopsy in all stages of drug development and clinical practice
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RA synovial tissue [15, 17]. Therefore, an FIH trial of an
anti–interleukin-17 monoclonal antibody performed in
patients with RA instead of healthy volunteers was a
logical approach [18].
Pharmacodynamic effects of investigational medicinal
product (IMP) in RA can be analyzed either in periph-
eral blood (plasma/serum/blood cells) or, with respect to
RA pathogenesis, in synovial tissue. Studies have shown
that expression of biomarkers in synovial tissue may be
independent of peripheral blood [19, 20].
Natural biological variability in disease activity and syn-
ovial tissue could be an important aspect in long-term
trials. In comparison to the variations observed in clinical
assessment, laboratory assessment including synovial tis-
sue changes are more stable and less susceptible to pla-
cebo response [21–23]. Analysis of synovial tissue during
clinical trials appears a sensible approach to document
changes directly at the site of inflammation and joint de-
struction. Published analysis of synovium has been mostly
limited to histology or single gene transcript [24, 25].
These approaches, although providing clinically useful in-
formation, were not granular enough to inform early
phase trial development. Studies of synovial biopsies using
state-of-the-art technologies and composite ontogenetic/
pathway analysis of gene clusters have been shown to be
more informative and relevant when compared to analysis
of individual markers [20, 26].
Finally, clinical outcomes require longer time follow
up and larger patient numbers that are permitted in
early phase studies [27]. Therefore there is an urgent
need to better quantify drug effect using alternative ap-
proaches in small proof-of-principle studies [6]. The
earlier on in clinical development a signal of pharmaco-
dynamics effect can be identified, fewer unnecessary
people will be recruited to trials, and novel drugs will
have a higher chance of succeeding through later phases.
Considering that synovial hyperplasia and its aggres-
sive potential are the hallmark of RA, analysis of early
pharmacodynamic effects of IMP in synovial tissue in
early phase clinical trials may be of great interest.
Synovial biopsy technique and safety – new approach on
board
In order to obtain synovial tissue from affected joint, ei-
ther an open method using surgical intervention or min-
imally invasive techniques may be used. The latter have
been increasingly utilised due to minimal burden on pa-
tients’ well being [24, 28].
A widely used method, a gold standard of synovial tissue
biopsy enabling visualisation of the joint, is to acquire tis-
sue at arthroscopy [27]. Although arthroscopic biopsies
are usually logistically more challenging, as they require
theatre settings and tend to be performed on larger joints,
smaller procedure rooms or the outpatient clinic setting
appeared feasible and accessible to rheumatologists [29].
The knee is the commonest site of arthroscopy, although
other smaller joints are accessible to arthroscopy when an
arthroscope of smaller diameter is used. This is essential
at early stages of the disease when predominantly hand
and wrist joints are affected. An important advantage of
arthroscopy is direct visualisation of the examined joint
enabling macroscopic evaluation of synovial tissue and
cartilage and obtaining adequate amount of tissue for
further sample processing [24].
Development and widespread use of ultrasound by
rheumatologists has supported the use of ultrasound-
guided synovial biopsies, merging the minimally invasive
needle biopsy with the advantage of visualized guidance
[30]. Although concerns about the validity of tissue sam-
pling for further sample processing and use other than
immunohistochemistry (e.g. molecular biology) have
been raised in the past [27], current knowledge provides
a firm evidence of good safety profile, tolerability and re-
producibility of high quality of sample collection even
from the small joints that are most frequently affected
joints in RA [30]. While previous studies obtained 6–8
samples per procedure, retrieving up to 12–15 samples
was shown to be tolerated by patients [28, 30].
In summary, recent advances in imaging, minimally in-
vasive biopsy procedures and tissue analysis offer a unique
opportunity to use synovial tissue in early drug develop-
ment given the discovery of new drivers and novel therap-
ies in RA. Learning from the oncologists’ approach of
performing whole genome transcriptomics on very small
samples of tissue in proof-of-concept studies [31], there is
the potential to adopt this approach in RA.
Obtaining high quality tissue and potential pitfalls
A major challenge of synovial tissue biopsies is obtaining
representative samples suitable for further analysis. Sev-
eral pitfalls during the process of tissue biopsy including
selection of site of biopsy deserve consideration.
First, it is essential to identify a joint with inflamed
synovium for biopsy. RA is a polyarticular disease affect-
ing predominantly hand joints. However, these may not
often be suitable for synovial biopsy despite availability
of minimally invasive techniques. Therefore the question
arises as to whether there are differences between the
synovium in the large and small joints. In general, cell
numbers present in synovial biopsies from knee joint or
small joint are comparable with a strong correlation for
the number of macrophages, T cells and plasma cells
along with IL-6 expression in the sublining layer across
joints. These results suggest that the inflammation in
one inflamed joint is generally representative of that in
other inflamed joints from the same patient. In contrast,
hyperplasia of intimal lining appears to depend on local
processes as the numbers of intimal macrophages or
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synovial fibroblasts in the lining layer do not correlate
between the different joints [32].
However, data obtained from open procedures (e.g. joint
replacement surgery) have revealed that significant tissue
heterogeneity is apparent within a single joint. It was
shown that number of differentially expressed genes be-
tween biopsies from the same patient was about three
times larger in orthopaedic than in arthroscopic biopsies
because open tissue biopsy included heterogeneous quality
samples from both inflamed and non-inflamed regions
[33]. Arthroscopic biopsies do allow direct visualisation of
the joint and therefore permit a targeted biopsy of affected
tissue, although despite this, arthroscopic biopsies still do
not guarantee adequate tissue for analysis [24, 34].
Ultrasound has a distinct advantage in the identification
of synovial tissue for biopsy by allowing assessment of both
synovial thickening and tissue vascularity, which can be
considered a surrogate for the direct visualisation of in-
flamed tissue. Pre-biopsy grey-scale US assessment of syno-
vitis predicts synovial tissue quantity/quality for histological
and RNA analyses in contrast to power Doppler [30].
Several studies analyzed histological variability be-
tween multiple specimens obtained during one biopsy
procedure. Histological analysis of tissue specimens ob-
tained from different areas the knee joint, including
those of apparent maximal and minimal involvement,
showed wide range of histological scores that reflects
natural biological variability [34, 35]. Other studies
showed similar pattern of cell infiltrates and expression
of selected mediators at mRNA or protein level when
compared synovial tissue originating from the junction
or suprapatellar pouch [36, 37]. However, it is preferen-
tial to obtain sections derived from multiple sites within
one joint for analysis based on natural variation within
synovial tissue [38, 39].
Synovial tissue analysis in trials – which method is the best?
As summarized above, the optimal approach to obtain rep-
resentative samples is to directly visualize inflamed tissue
arthroscopically or with ultrasound. Direct visualization
during biopsy minimizes sampling error, enables acquisi-
tion of biopsies from precise locations within joints and
provides reproducible good quality tissues. Available tech-
niques for synovial tissue analysis will now be summarized
(Fig. 2).
Fig. 2 Methods of synovial tissue analysis with implications for drug development
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Histological analysis and immunohistochemistry (IHC)
The typical feature of RA synovium is synovial thickening
in the lining layer due to infiltration of monocytes/macro-
phages and excessive proliferation of synovial fibroblasts,
in the sublining layer by marked cellular infiltrate, which
includes synovial fibroblasts, macrophages, CD4+ and
CD8+ T cells, B cells, plasma cells, dendritic and mast
cells, in addition to increased vascularity due to enhanced
angiogenesis [40]. Immune cells can be grouped into fol-
licular structures (follicular synovitis, mostly B cells) in
30–40 % of patients or be randomly distributed within the
sublining layer (diffuse synovitis, predominantly CD68+
cells). In contrast, another type known as pauci-immune
synovitis shows hardly any infiltrating immune-cells and
may be present in active disease [41].
Histology and IHC enable visualization of cell/protein
markers expression and distribution in synovial tissue. An
accurate estimate of the overall joint should be satisfactorily
provided by analysis of cumulative area of 2.5 mm2 from at
least 3 biopsy specimens when sample is obtained during
arthroplasty, arthroscopy or blind synovial tissue biopsy
from small or large joints [42, 43]. However, 6–8 tissue
samples are usually obtained for further analysis [28, 30].
US-guided biopsy was shown to approach 92.5–100 % suc-
cess in acquisition of histologically reliable tissues [30, 42].
Methods used for quantitative analysis of IHC data
have both advantages and limitations [24, 38, 39]. One
potential error may occur due to lack of internal
normalization or non-specific accumulation of pigmen-
ted precipitate detected by enzymatic processes [39]. Al-
though manual cell counting is considered a standard
histological analysis, it is time consuming and faces
several other pitfalls, e.g. observer bias, limited number
and selection of fields to be analyzed that may cause sig-
nificant limitation in large clinical trials. Widely used
semi-quantitative analysis and latest techniques using
computer based digital image analysis may minimize
these errors, are acceptable for whole tissue analysis of
widespread targets, lack field selection errors and bias
may be minimized by using grading scales and analyses
performed by independent readers.
Semi-quantitative histopathological scoring system (from
0, absent to 3, strong) was used to evaluate 3 features of
chronic synovitis: enlargement of lining cell layer, cellular
density of synovial stroma and leukocytic infiltrate. The
sum provided the synovitis score (0–1, no synovitis; 2–4,
low-grade synovitis; 5–9, high-grade synovitis) that showed
61.7 % sensitivity and 96.1 % specificity for RA-related
high-grade synovitis and contributed to the diagnostics of
rheumatic and non-rheumatic joint diseases [44].
Western blot and mass spectrometry
The western blot is an analytical technique used to detect
specific proteins of interest in tissue homogenate or
extract but has limited value in clinical trials. Instead, ana-
lyses using mass spectrometry may become a promising
method to analyze proteome from whole tissue extracts.
Matrix assisted laser desorption/ionization combined with
time-of-flight detection (MALDI-TOF) was recently
shown to distinguish different subgroups of juvenile idio-
pathic arthritis [45]. Imaging mass spectrometry that com-
bines morphology and mass spectrometry has been used
to illustrate various mass spectra generated from proteins
expressed in RA and osteoarthritis synovial tissue [46]. In
theory MALDI-TOF also offers an opportunity to quanti-
tatively assess tissue level drug exposure directly, although
this has not previously been done. Mass cytometry, previ-
ously used for cell suspensions, has recently been coupled
with IHC and immunocytochemical methods with high-
resolution laser ablation to CyTOF mass cytometry [47].
Although this method has only been applied to malignant
tissue so far, it is a candidate approach that could identify
over 100 protein markers in conjunction with a CyTOF
machine enabling high-dimensional, single-cell analysis of
cell type and state, cell interactions and tissue structure in
future targeted diagnosis and therapies [47].
In situ hybridization
Similar to IHC, in situ hybridization shows a target of
interest at the transcriptional level (messenger RNA,
mRNA) and enables visualisation of mRNA distribution
within tissue. Information obtained by in situ hybridization
can be reliably confirmed at the protein level by IHC [48].
Albeit that this method is powerful enough to detect even
small non-coding RNAs such as miRNAs, it is time con-
suming, requires multiple steps to be optimized for every
single target or tissue and, like IHC, enables detection of
only limited number of genes.
Single/multiple gene analysis and transcriptome profiling
Gene expression technology has expanded enormously in
recent years and enables analysis of single genes, groups of
genes or whole genome wide expression profiles including
protein-coding or non-coding regions, although sufficient
tissue is needed for RNA extraction. Needle arthroscopy
using 2-mm grasping forceps and obtaining 6 biopsy speci-
mens provided at least 15–50 mg for further RNA analysis
[49]. Other studies using needle arthroscopy approach
showed that at least 4 biopsy samples provided 1–2 μg of
total RNA [50, 51]. Yield from ultrasound guided synovial
tissue biopsy taking 6 samples with 16/14G quick core nee-
dles provided at least 10 mg of synovial tissue for RNA iso-
lation, with a median RNA yield 0.54–0.89 μg/10 mg tissue.
The yield varied according to joint size with a tendency for
lower yields obtained from small joints [30]. General, > 1
ug of RNA is needed for transcriptomic studies, particularly
RNA-sequencing [52], which is generally at the threshold
of total RNA obtained from synovial tissue biopsies. A
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relatively new approach to overcome this issue is a
low-input 5’- or 3’-RNA-sequencing, where the ter-
minal 300–500 bp of either the 5’- or 3’-end of the
mRNA is sequenced instead of the entire transcript
and low quantities of starting material (as low as 1 ng
total RNA) can be used [53].
Considering serial tissue biopsies for clinical trial pur-
poses, similar numbers of biopsies as well as RNA yield
was obtained in subsequent biopsies 12 weeks apart and
demonstrated evidence of tissue level pharmacodynamic
response [30]. These data suggest that ultrasound-
guided synovial tissue biopsies have the potential to be
taken forward as a method of choice in the experimental
setting associated with drug development.
In keeping with sampling errors discussed above, tran-
scriptome profiling also carries a risk of error due to bio-
logical or technical variability [54]. The manner by which
these factors influence gene expression profiles remains
unsure as changes in transcriptome can occur very rap-
idly: while one study emphasized the major impact of bio-
logical variability (age, sex, time of the day, cellular
composition), another study showed that technical vari-
ability is of greater importance [54, 55]. Also, intra-patient
variations in biopsies are smaller than inter-patient varia-
tions, reflecting unique mRNA signatures of each patient
rather than tissue heterogeneity [56].
Microarray technology, that uses selected probes
placed on solid matrix, is limited by the reliance upon
existing knowledge about genome sequence, high back-
ground noise and a limited dynamic range [31]. In con-
trast, RNA sequencing enables studying the whole
transcriptome including gene boundaries and introns,
splicing diversity as well as detection of small RNAs in a
high-throughput and quantitative manner [57].
Transcriptome interpretation
Studies using state-of-the-art technologies and compos-
ite ontogenetic/pathway analysis s have been shown to
be more informative and relevant compared to analysis
of individual markers [24–26]. Such comprehensive ana-
lysis in tissue/blood may indentify single genes or gene
combinations/subsets that may have a predictive/diag-
nostic value and may be taken forward for further valid-
ation [58–60]. For example, a set of 20 genes selected
from microarray analysis of white blood cells had 90 %
sensitivity and 70 % specificity whilst a combination of
only 8 genes had 80 % sensitivity and 100 % specificity
to distinguish RA responders or non-responders to
infliximab [58]. However, expression profiles, providing
e.g. a gene expression signature predictive of therapeutic
response, are often inconsistent across studies [59].
Protocol standardization from preanalytical phase until
data analysis is therefore crucial for obtaining reliable,
consistent and reproducible data [25, 27]. Also, selection
of the same tissue type, patients and clinical parameters
are important to be considered when different studies
are compared [61]. Importantly, genome-wide expres-
sion profiling, changes in transcriptome, pathway/ontol-
ogy analysis, and comparison between different cell
types/compartments may unravel complex molecular in-
teractions and reflect responses to therapy.
What have we learned from histopathological analysis of
synovial biopsies in clinical trials?
As mentioned above, the increasing pressure to obtain
accurate and reliable outcome data in early phase clin-
ical trials draws attention to synovial biopsies. Recogni-
tion of markers of early drug response at synovial tissue
level would be of great value in proof-of-concept studies
and would help to make early go/no go decisions on
progression of the drug to next phase level. Also, mul-
tiple studies using IHC have revealed association be-
tween baseline synovial tissue biomarkers, their change
upon therapeutic intervention and future disease re-
sponse. Much of the data were generated after exposure
to very well known, newly introduced and experimental
drugs, and are summarized in Table 1. The overview is
based on a complex literature review providing results of
original studies and summaries of systematic reviews.
These data must be compared and interpreted with cau-
tion given the different timelines, disease characteristics of
patient groups and immunolabeling, e.g. B cell markers
CD19, CD22 and CD20 that are not jointly expressed dur-
ing the maturation of B cells [62–65]. As some data are in
contrast to changes documented in peripheral blood, com-
position of synovial tissue infiltrates and expression of me-
diators may drive local inflammation or be associated with
early relapse of RA and underscore the importance of look-
ing at synovial tissue [62, 64]. Also, the absence of clinical
effect of a study drug/placebo is accompanied by the lack
of changes in sequential biopsies [21, 66–68]. This supports
the importance of synovial tissue analysis during treatment
that may be more sensitive than clinical assessment.
Synovial transcriptome: a new biomarker?
Data on complex gene expression analysis on RA, osteo-
arthritis and healthy synovial tissue suggested that this
approach could be taken forward to test transcriptome
responses following treatment at synovial tissue level
[69, 70]. Both immune and stromal cells contribute to
tissue heterogeneity resulting in clusters of differentially
expressed genes in keeping with different pathophysiologic
processes across patients [20, 41, 71]. A group of RA
patients with high inflammatory gene expression pattern
indicated involvement of immunity and defence pathways
and activation of B and T cells while the other group
showed predominantly involvement of cell-communication,
developmental and fibroblast-dedifferentiation pathways
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Table 1 Overview of immunohistopathological data obtained from small proof-of-concept studies using synovial biopsies in RA
Drug Timing of
biopsies
Key finding Reference
DMARDs/anti-TNF/
experimental
2–16 weeks Number of CD68+ macrophages in sublining synovial layer is
a good biomarker of therapeutic response.
[76–79]
Methotrexate 16 weeks Decrease in the numbers of inflammatory cells, including CD3+
and CD8+ T cells, CD38+ plasma cells, CD68+ macrophages
(lining layer), inflammatory and destructive mediators
(Ki67, IL-1β, TNF-α, E-selectin, ICAM-1, VCAM-1, MMP-1).
Responders displayed a reduction in the expression of all ICAM-1,
VCAM-1, TNF-α and IL-1 β.
[80, 81]
Methotrexate 12 weeks No change in synovial hyperplasia, lymphoplasmocytic infiltrate,
CD68+ macrophages, CD3+ T cells and CD138+ plasma cells
[50]
Leflunomide 16 weeks Decrease in the numbers CD68+ macrophages (sublining),
inflammatory and destructive mediators (ICAM-1, VCAM-1, MMP-1).
Responders displayed a reduction in the expression of ICAM-1,
VCAM-1 and TNF-α.
[81]
Prednisolone 24 h Decrease in the expression of TNF-α (lining and sublining), IL-8 (lining),
as well as reduced synovial fluid IL-8 levels. Change in TNF-α correlated
with clinical response to, and subsequent relapse after therapy
[82]
Prednisolone 2 weeks Reduction in the number of sublining synovial macrophages, a trend
toward decreased infiltration by CD4+ T cells, CD38+ plasma cells,
and CD55+ fibroblast-like synoviocytes
[76]
Infliximab (3 mg/kg) 48 h/
4 weeks
Reduced number of CD68+ intimal macrophages after 48 h, a trend
to decreased amount of CD38+ plasma cells, CD3+ T cells, sublining
CD68+ macrophages after 48 h/4 weeks. Decreased numbers of CD3+,
CD38+ and both intinal and sublining CD68+ cells were observed in
clinical responders after 4 weeks.
[23]
Infliximab (10 mg/kg) 2 weeks Reduction in the numbers of infiltrating synovial CD3+ T cells, CD22+ B cells,
CD68+ macrophages and in the expression of IL-8, MCP-1 and TNF-α. High
levels of synovial TNF-α prior to treatment may predict responsiveness to therapy.
[83, 84]
Rituximab 4 weeks Incomplete depletion of CD22+ B cells, no correlation with the change in DAS28. [62]
Rituximab 4 weeks
16 weeks
CD19+ B cells significantly but incompletely decreased at 4 weeks, with
further reduction at 16 weeks in some patients. Decrease in CD68+
macrophages at 4 and 16 weeks, CD3+ T cells decreased at 16 weeks.
The reduction of CD138+ plasma cells predicted clinical improvement
at 24 weeks.
[64]
Rituximab 12 weeks Depletion of CD20+ B cells, trend to decrease in CD68+ macrophages.
No correlations between changes in CD20+ or CD68+ and changes in
the DAS28. Positivity for circulating IgM ACPA, in combination with a
high infiltration of CD79a + B cells is a predictor of clinical outcome
after rituximab.
[51, 65]
Tocilizumab 12 weeks Decrease in synovial hyperplasia, lymphoplasmocytic infiltrate, CD68+
macrophages, CD3+ T cells and CD138+ plasma cells
[50]
Anakinra + pegsunercept 4 weeks
52 weeks
Decrease in number of CD3+ T cells and TGFβ expression as biomarker
therapeutic response at weeks 4 and 52 of combination therapy.
Baseline CD3+ and sublining CD68+ infiltration, VEGF and TGFβ
expression were predictive of subsequent structural outcome
at 6 or 12 months.
[19]
CCR1 antagonist 2 weeks Reduction in overall cellularity, number of CD4+ and CD8+ T cells,
CD68+ macrophages and the number of CCR1+ cells.
[22]
RecIL-10 12 weeks No significant change in number of inflammatory cells or in the
scores for the expression of cytokines.
[85]
IL-1 receptor antagonist 24 weeks Reduction in intimal and sublining CD68+ macrophages and CD3+ lymphocytes. [86]
Anti-CCL2 antibody 6 weeks No immunohistologic changes. [66]
C5aR-antagonis 4 weeks No immunohistologic changes. [67]
IFN-β (18/36/54 million
IU/week)
4 weeks
12 weeks
Decrease in number of CD3+ T cells at 4 weeks and CD38+ plasma cells at 12 weeks along with
changes of several inflammatory and destructive molecules (e.g. MMP-1, IL-6 or IL-1β).
[87]
IFN-β (6.6/132 μg/week) 24 weeks No changes in synovial tissue infiltrates. [68]
Filkova et al. BMC Musculoskeletal Disorders  (2016) 17:172 Page 7 of 11
[9, 20, 41]. Similarly, gene expression in synovial tissue
from patients with early RA identified at least two patterns
of synovitis, one of which resembled long-standing RA
[72]. In addition, distinct baseline synovial gene expression
signature reflecting phenotypes of RA synovium (lymphoid,
myeloid, low inflammatory, fibroid) may be predictive of
treatment response: synovial myeloid, but not lymphoid,
gene signature expression was higher in patients with good
compared with poor response to anti-TNFα therapy [71].
These data suggest that RA patients with different pathway
activation may need different therapeutic approaches. Ex-
amples of comprehensive gene expression analysis aiming
for individualized therapy and understanding of mode of
action of novel therapies are summarized in Table 2.
Importantly, the differences between study designs and
selection of patients should be considered. For example,
treatment with methotrexate, tocilizumab and rituximab
had similar molecular effects on transcriptomic changes
(albeit of different magnitudes) in the RA synovium,
which were distinct from the molecular changes induced
by adalimumab [50, 51, 73]. It is important to notice that
patients included in these trials were at different stages of
the disease, since patients on tocilizumab or methotrexate
were treatment naive, patients on adalimumab had failed
DMARD therapy and patients commencing rituximab
were both DMARDs anti-TNF failures. Although to date
transcriptome analysis has been directed towards predic-
tion of clinical response, its greatest strength may lie in
helping understand of drug mode of action.
Is transcriptome analysis in peripheral blood superior to
synovial tissue?
Compared to synovial biopsy, obtaining peripheral blood
to explore new biomarkers of treatment response may
be convenient due to the quick and non-invasive ap-
proach. However, there is evidence that transcriptome
analysis in peripheral blood and synovial tissue may be
of different value:
Table 2 Overview of gene expression analysis obtained from small proof-of-concept studies using synovial biopsies in RA
Drug Timing of biopsies Key finding Reference
Infliximab Baseline Differential baseline gene expression in responders and non-responders.
Overexpression of genes involved in T-cell mediated immunity, cell
surface receptor mediated signal transduction, major histocompatibility
complex II (MHCII)-mediated immunity, cell adhesion, cytokine and
chemokine mediated signalling, cell adhesion mediated signalling,
signal transduction, and macrophage-mediated immunity identified
in responders.
[88]
Infliximab 9 weeks Unique baseline transcriptome in all patients. 279 differentially expressed
genes between good responders and non-responders. Significant change
in expression of 115 genes in the good responding group involved in
immune response, cell communication, signal transduction and chemotaxis.
[56]
Adalimumab 12 weeks Deregulated baseline expression of 439 genes involved in cell cycle
and immune responses in good vs. poor responders. Differential
expression of 632 genes enrolled in cell division, signal transduction,
antigen processing/presentation, T-cell activation, and apoptosis
upon adalimumab treatment in a group of good responders.
[73]
Rituximab 12 weeks Deregulated baseline expression of 2458 genes involved in immunoglobulin
clusters, antigen processing and presentation via MHCII in non-responders
vs. responders. Treatment with rituximab resulted in downregulation of
220 genes enriched in immunoglobulin clusters, chemotaxis, leukocyte
activation and immune responses; upregulation of 329 genes involved
in cell development and wound healing.
[51]
Rituximab 12 weeks
21 months
Baseline differential expression of genes involved in T cell and macrophage
function, remodelling and interferon-α biology between non-responders
vs. responders at months 3, 9 and 21. Downregulation of CD20 at 3
and 12 months, differential expression of multiple genes involved in
B and T cell biology at 21 months (e.g. CD27, CD38, CD8, CD52, CTLA4,
CD122, FOXP3, IL-6, IL-12, IL-13, IL-17RA, IL-23a, IL-32, CCL5, MMP3, FASLG)
[89]
Tocilizumab 12 weeks Downregulation of 3413 genes involved in cytokine/chemokine pathways
and T cell activation, upregulation of 3270 genes involved in healing
process. Downregulation of genes involved in induction of apoptosis
and myeloid cell differentiation, and upregulation of genes involved in
regulation of Ras protein signal transduction and ubiquitin-dependent
protein catabolic processes observed in responders achieving remission
at 6 months.
[50]
Methotrexate 12 weeks Downregulation of 586 genes enriched in T cell activation and immune
response pathways, upregulation of 610 genes. Downregulation of genes
enrolled in cell division in responders achieving remission at 6 months.
[50]
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While gene expression profiling in RA synovial tissue
mentioned above [20] revealed 2 groups of patients
based on differential involvement of molecular pathways
in keeping with the immunohistopathological picture,
gene expression profiles in peripheral blood did not re-
flect the differential tissue pathology.
Gene expression analysis using a microarray approach
was performed on RNA from peripheral blood mono-
nuclear cells (PBMC) 72 h after a single dose of etanercept
[74]. Although a combination of 46 genes at baseline level
did not predict therapeutic response, the change in their ex-
pression was associated with disease activity at 3 months.
Pathway analysis in PBMC revealed TNFα and IL-6 related
downstream changes in responders while TNF-α related
mechanisms were detected in non-responders suggesting
differential regulation in non-responders [74]. Also, inflixi-
mab dampened immune responses in PBMC one month
after first dose [75]. It was shown that all RA patients have
a similar magnitude of down-regulation of genes involved
in inflammation, angiogenesis and T and B cell activation
irrespective of clinical response evaluated after 16 weeks,
highlighting that the transcript changes observed in periph-
eral blood correlate less well with clinical response com-
pared to synovium.
Conclusions
There is grooving evidence to justify the use of synovial tis-
sue in early drug development. Synovial tissue represents
an appropriate compartment to be studied in patients with
inflammatory arthritis and provides information that is dis-
tinct from peripheral blood in the context of RA. Modern
techniques have made the procedure much more access-
ible and ultrasound guided biopsies represent a safe and
acceptable option. Advances in analytic technologies allow-
ing transcriptomic level of analysis can provide unique in-
side to target organ/tissue following the exposure to IMP.
However, there are still caveats with regard to both the
choice of technique and analytical methods. Therefore the
significance of synovial biopsy remains to be determined in
future clinical trials.
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